Meijer L, Chrétien E, Ravel D. Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer's Disease and Down Syndrome. J Alzheimers Dis. 2024;101(s1):S95-S113. PubMed. Correction.
Recommends
Please login to recommend the paper.
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.